NewAmsterdam Pharma Net Income vs. Total Asset

What growth prospects exist in Biotechnology sector? Can NewAmsterdam capture new markets? Factors like these will boost the valuation of NewAmsterdam Pharma. Anticipated expansion of NewAmsterdam directly elevates investor willingness to pay premium valuations. Valuation analysis balances hard financial data with qualitative growth assessments. While each NewAmsterdam Pharma valuation metric matters, prioritizing which indicators carry greater predictive weight remains essential.
Revenue Per Share
0.311
Quarterly Revenue Growth
(0.99)
Return On Assets
(0.21)
Return On Equity
(0.40)
Investors evaluate NewAmsterdam Pharma using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating NewAmsterdam Pharma's intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Investment professionals apply varied valuation frameworks to compute inherent worth and acquire positions when market prices trade at discounts to calculated value. External factors like market trends, sector rotation, and investor psychology can cause NewAmsterdam Pharma's market price to deviate significantly from intrinsic value.
It's important to distinguish between NewAmsterdam Pharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding NewAmsterdam Pharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, NewAmsterdam Pharma's market price signifies the transaction level at which participants voluntarily complete trades.

NewAmsterdam Pharma Total Asset vs. Net Income Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining NewAmsterdam Pharma's current stock value. Our valuation model uses many indicators to compare NewAmsterdam Pharma value to that of its competitors to determine the firm's financial worth.
NewAmsterdam Pharma is rated below average in net income category among its peers. It is regarded fifth in total asset category among its peers . NewAmsterdam Pharma reported Net Loss of (217.44 Million) in 2025. Comparative valuation analysis is a catch-all technique that is used if you cannot value NewAmsterdam Pharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

NewAmsterdam Total Asset vs. Net Income

Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

NewAmsterdam Pharma

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

 = 
(241.6 M)
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.

NewAmsterdam Pharma

Total Asset

 = 

Tangible Assets

+

Intangible Assets

 = 
864.62 M
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.

NewAmsterdam Total Asset Comparison

NewAmsterdam Pharma is currently under evaluation in total asset category among its peers.

NewAmsterdam Pharma Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in NewAmsterdam Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, NewAmsterdam Pharma will eventually generate negative long term returns. The profitability progress is the general direction of NewAmsterdam Pharma's change in net profit over the period of time. It can combine multiple indicators of NewAmsterdam Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income5.1 M3.8 M
Net Interest Income19.4 M20.4 M
Interest Income19.4 M20.4 M
Operating Income-158.7 M-150.7 M
Net Loss-217.4 M-206.6 M
Income Before Tax-217.4 M-206.6 M
Total Other Income Expense Net-58.8 M-55.8 M
Net Loss-217.4 M-206.6 M
Income Tax Expense(900.00)(855.00)
Net Loss(2.94)(3.09)
Income Quality 0.75  0.61 
Net Income Per E B T 1.15  1.10 

NewAmsterdam Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on NewAmsterdam Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of NewAmsterdam Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the NewAmsterdam Pharma's important profitability drivers and their relationship over time.

NewAmsterdam Pharma Earnings per Share Projection vs Actual

Use NewAmsterdam Pharma in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NewAmsterdam Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NewAmsterdam Pharma will appreciate offsetting losses from the drop in the long position's value.

NewAmsterdam Pharma Pair Trading

NewAmsterdam Pharma Pair Trading Analysis

The ability to find closely correlated positions to NewAmsterdam Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NewAmsterdam Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NewAmsterdam Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NewAmsterdam Pharma to buy it.
The correlation of NewAmsterdam Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NewAmsterdam Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NewAmsterdam Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NewAmsterdam Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your NewAmsterdam Pharma position

In addition to having NewAmsterdam Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Technology Thematic Idea Now

Technology
Technology Theme
Companies that are involved in development or distribution of technologically based goods and services such as software, IT or electronics. The Technology theme has 30 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Technology Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for NewAmsterdam Stock Analysis

When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.